July 1, 2022
Early Study Finds New Lymphoma Drug Effective BookmarkGeorge Lundberg, MD
According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.
July 28, 2021
New Chronic Lymphocytic Leukemia Treatments 2021 BookmarkGeorge Lundberg, MD
TheSocialMedwork outlines several new drugs for treating chronic lymphocytic leukemia, including Brukinsa (zanubrutinib).
December 2, 2019
FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor Shrinkage BookmarkGeorge Lundberg, MD
Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.
Go to full article published by the U.S. Food and Drug Administration (FDA).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.